239 related articles for article (PubMed ID: 33267959)
1. Individualized ovarian stimulation for in vitro fertilization: a multicenter, open label, exploratory study with a mixed protocol of follitropin delta and highly purified human menopausal gonadotropin.
Bissonnette F; Minano Masip J; Kadoch IJ; Librach C; Sampalis J; Yuzpe A
Fertil Steril; 2021 Apr; 115(4):991-1000. PubMed ID: 33267959
[TBL] [Abstract][Full Text] [Related]
2. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial.
Nyboe Andersen A; Nelson SM; Fauser BC; García-Velasco JA; Klein BM; Arce JC;
Fertil Steril; 2017 Feb; 107(2):387-396.e4. PubMed ID: 27912901
[TBL] [Abstract][Full Text] [Related]
3. A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF/ICSI patients.
Qiao J; Zhang Y; Liang X; Ho T; Huang HY; Kim SH; Goethberg M; Mannaerts B; Arce JC
Hum Reprod; 2021 Aug; 36(9):2452-2462. PubMed ID: 34179971
[TBL] [Abstract][Full Text] [Related]
4. A randomized, controlled, first-in-patient trial of choriogonadotropin beta added to follitropin delta in women undergoing ovarian stimulation in a long GnRH agonist protocol.
Fernández Sánchez M; Višnová H; Larsson P; Yding Andersen C; Filicori M; Blockeel C; Pinborg A; Khalaf Y; Mannaerts B;
Hum Reprod; 2022 May; 37(6):1161-1174. PubMed ID: 35451013
[TBL] [Abstract][Full Text] [Related]
5. Randomized, assessor-blind, antimüllerian hormone-stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta.
Ishihara O; Klein BM; Arce JC;
Fertil Steril; 2021 Jun; 115(6):1478-1486. PubMed ID: 33272623
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes of ovarian stimulation with follitropin delta in a mixed regimen with HP-hMG: a real-world retrospective analysise.
Lim LJ; Kit AMF; Wong PS
Med J Malaysia; 2024 May; 79(3):275-280. PubMed ID: 38817059
[TBL] [Abstract][Full Text] [Related]
7. Individualization of the starting dose of follitropin delta reduces the overall OHSS risk and/or the need for additional preventive interventions: cumulative data over three stimulation cycles.
Fernández-Sánchez M; Visnova H; Yuzpe A; Klein BM; Mannaerts B; Arce JC;
Reprod Biomed Online; 2019 Apr; 38(4):528-537. PubMed ID: 30713022
[TBL] [Abstract][Full Text] [Related]
8. Comparative clinical outcome following individualized follitropin delta dosing in Chinese women undergoing ovarian stimulation for in vitro fertilization /intracytoplasmic sperm injection.
Yang R; Zhang Y; Liang X; Song X; Wei Z; Liu J; Yang Y; Tan J; Zhang Q; Sun Y; Wang W; Qian W; Jin L; Wang S; Xu Y; Yang J; Goethberg M; Mannaerts B; Wu W; Zheng Z; Qiao J
Reprod Biol Endocrinol; 2022 Oct; 20(1):147. PubMed ID: 36195924
[TBL] [Abstract][Full Text] [Related]
9. Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF/ICSI patients: a randomized controlled trial.
Ishihara O; Arce JC;
Reprod Biomed Online; 2021 May; 42(5):909-918. PubMed ID: 33722477
[TBL] [Abstract][Full Text] [Related]
10. In vitro fertilisation with recombinant follicle stimulating hormone requires less IU usage compared with highly purified human menopausal gonadotrophin: results from a European retrospective observational chart review.
Trew GH; Brown AP; Gillard S; Blackmore S; Clewlow C; O'Donohoe P; Wasiak R
Reprod Biol Endocrinol; 2010 Nov; 8():137. PubMed ID: 21059191
[TBL] [Abstract][Full Text] [Related]
11. Corifollitropin alfa followed by highly purified HMG versus recombinant FSH in young poor ovarian responders: a multicentre randomized controlled clinical trial.
Drakopoulos P; Vuong TNL; Ho NAV; Vaiarelli A; Ho MT; Blockeel C; Camus M; Lam AT; van de Vijver A; Humaidan P; Tournaye H; Polyzos NP
Hum Reprod; 2017 Nov; 32(11):2225-2233. PubMed ID: 29040589
[TBL] [Abstract][Full Text] [Related]
12. Follitropin delta combined with menotropin in patients at risk for poor ovarian response during in vitro fertilization cycles: a prospective controlled clinical study.
Duarte-Filho OB; Miyadahira EH; Matsumoto L; Yamakami LYS; Tomioka RB; Podgaec S
Reprod Biol Endocrinol; 2024 Jan; 22(1):7. PubMed ID: 38166856
[TBL] [Abstract][Full Text] [Related]
13. Low risk of OHSS with follitropin delta use in women with different polycystic ovary syndrome phenotypes: a retrospective case series.
Yacoub S; Cadesky K; Casper RF
J Ovarian Res; 2021 Feb; 14(1):31. PubMed ID: 33579321
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes of potential high responders after individualized FSH dosing based on anti-Müllerian hormone and body weight.
Višnová H; Papaleo E; Martin FS; Koziol K; Klein BM; Mannaerts B
Reprod Biomed Online; 2021 Dec; 43(6):1019-1026. PubMed ID: 34756645
[TBL] [Abstract][Full Text] [Related]
15. Corifollitropin alfa compared with follitropin beta in poor responders undergoing ICSI: a randomized controlled trial.
Kolibianakis EM; Venetis CA; Bosdou JK; Zepiridis L; Chatzimeletiou K; Makedos A; Masouridou S; Triantafillidis S; Mitsoli A; Tarlatzis BC
Hum Reprod; 2015 Feb; 30(2):432-40. PubMed ID: 25492411
[TBL] [Abstract][Full Text] [Related]
16. Could the addition of hp-hMG and GnRH antagonists modulate the response in IVF-ICSI cycles?
Requena A; Landeras JL; Martínez-Navarro L; Calatayud C; Sánchez F; Maldonado V; Muñoz M; Fernández M; González A; López S; López R; Pacheco A; Calderón G; Martínez V
Hum Fertil (Camb); 2010 Mar; 13(1):41-9. PubMed ID: 20384441
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of follitropin delta for ovarian stimulation in vitro fertilization/ intracytoplasmic sperm injection cycles: a systematic review with meta-analysis.
Palomba S; Caserta D; Levi-Setti PE; Busnelli A
J Ovarian Res; 2024 Mar; 17(1):60. PubMed ID: 38486276
[TBL] [Abstract][Full Text] [Related]
18. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimüllerian hormone-stratified, dose-response trial in women undergoing in vitro fertilization/intracytoplasmic sperm injection.
Arce JC; Andersen AN; Fernández-Sánchez M; Visnova H; Bosch E; García-Velasco JA; Barri P; de Sutter P; Klein BM; Fauser BC
Fertil Steril; 2014 Dec; 102(6):1633-40.e5. PubMed ID: 25256937
[TBL] [Abstract][Full Text] [Related]
19. The effect of human menopausal gonadotrophin and highly purified, urine-derived follicle stimulating hormone on the outcome of in-vitro fertilization in down-regulated normogonadotrophic women.
Westergaard LG; Erb K; Laursen S; Rasmussen PE; Rex S
Hum Reprod; 1996 Jun; 11(6):1209-13. PubMed ID: 8671425
[TBL] [Abstract][Full Text] [Related]
20. Live birth rates following individualized dosing algorithm of follitropin delta in a long GnRH agonist protocol.
Sánchez MF; Larsson P; Serrano MF; Bosch E; Velasco JAG; López ES; Mannaerts B
Reprod Biol Endocrinol; 2023 May; 21(1):45. PubMed ID: 37194068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
